Does Rallies track congressional trades in NVS?

Yes. Rallies tracks politician and congressional stock disclosures for NVS, including reported purchases, sales, dates, owners, and trade amounts when available.

Is NVS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for NVS. It does not provide personalized investment advice.

NVS (Novartis AG) Stock Analysis - Politician Trades

Novartis AG (NVS) is a publicly traded Healthcare sector company. As of May 20, 2026, NVS trades at $151.00 with a market cap of $284.59B and a P/E ratio of 0.00. NVS moved -0.01% today. Year to date, NVS is +8.59%; over the trailing twelve months it is +35.89%. Its 52-week range spans $96.06 to $170.46. Analyst consensus is buy with an average price target of $167.22. Rallies surfaces NVS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Which politicians traded NVS stock?

Recent politician trading activity in NVS includes disclosures from Lisa McClain, Lisa McClain, Sheldon Whitehouse, Sheldon Whitehouse, and Thomas R. Carper. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.

NVS Key Metrics

Key financial metrics for NVS
Metric	Value
Price	$151.00
Market Cap	$284.59B
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	4.74%
52-Week High	$170.46
52-Week Low	$96.06
Volume	1.11M
Avg Volume	0
Revenue (TTM)	$0
Net Income	$0
Gross Margin	0.00%

Congressional Trades in NVS

Lisa McClain sale (partial) NVS on Sep 25, 2025 (amount: $15.00K) for Spouse.
Lisa McClain purchase NVS on Sep 11, 2025 (amount: $15.00K) for Spouse.
Sheldon Whitehouse sale (partial) NVS on Apr 9, 2024 (amount: $15.00K) for Self.
Sheldon Whitehouse purchase NVS on Sep 20, 2023 (amount: $50.00K) for Self.
Thomas R. Carper purchase NVS on Apr 26, 2023 (amount: $15.00K) for Spouse.

Latest NVS News

Novartis Partners on Brain Transporter Tech as Leqembi Sales Expected at $900M — May 20, 2026
Novartis to outsource 35% of API, 25% of biologics manufacturing, saves $120 M — May 12, 2026
Novartis Secures Three-Part Bond Funding in Record €31B European Debt Sale — May 6, 2026
Novartis jumps as Q1 update reassures on guidance and accelerating key-drug growth — Apr 30, 2026
Novartis slides as Q1 results miss estimates amid Entresto generic pressure — Apr 28, 2026

NVS Analyst Consensus

5 analysts cover NVS: 0 strong buy, 3 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $167.22.

Common questions about NVS

Which politicians traded NVS stock?: Recent politician trading activity in NVS includes disclosures from Lisa McClain, Lisa McClain, Sheldon Whitehouse, Sheldon Whitehouse, and Thomas R. Carper. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in NVS?: Yes. Rallies tracks politician and congressional stock disclosures for NVS, including reported purchases, sales, dates, owners, and trade amounts when available.
Is NVS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for NVS. It does not provide personalized investment advice.